SANTA MONICA, Calif., May 7 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has begun due diligence to either purchase or build its own secure cryogenic stem cell bank for the storage of multiple stem cell products including umbilical cord blood stem cells.
"Over the long term, having our own facility will reduce the cost for both the processing and storage of our clients' stem cells," said founder and CEO Matthew Schissler. "Additionally, it allows CBAI to pursue new sources of revenue such as the storage of adipose tissue and peripheral blood stem cells processing and storage, and research grants much quicker than under the current structure of outsourced relationships."
"We can't grow to the size and position we seek for the future without our own laboratory. This is an important strategic step to securing further industry leadership and differentiation," Mr. Schissler said.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 email@example.com
|SOURCE Cord Blood America, Inc.|
Copyright©2009 PR Newswire.
All rights reserved